Category - Markets

H.C. Wainwright initiated coverage of ZIOPHARM Oncology (NASDAQ:ZIOP) with a “buy” rating and $9.50 price target. The stock closed at $5.85 on May 31. Anchored by two cutting-edge technologies, ZIOPHARM is focused on...

William Blair initiated coverage of Ovid Therapeutics (NASDAQ:OVID) with an “outperform” rating and fair value estimate of $28. The stock closed at $14.57 on May 26. Ovid is focused on rare neurological disorders. Its...

William Blair launched coverage of Biohaven Pharmaceutical Holding (NYSE:BHVN) with an “outperform” rating and fair value estimate of $46. The stock closed at $23.79 on May 26. Biohaven is developing a portfolio of...

H.C. Wainwright initiated coverage of Vanda Pharmaceuticals (NASDAQ:VNDA) with a “buy” rating and $18 price target. The stock closed at $14.05 on May 26. “We think Vanda now has a solid base business, with both Fanapt...

William Blair initiated coverage of Albany Molecular Research (NASDAQ:AMRI) with an “outperform” rating. The stock closed at $17.31 on May 19. Albany Molecular is a leading provider of discovery and formulation...

Leerink launched coverage of Verona Pharma (NADAQ:VRNA; AIM:VRP) with a “buy” rating and $22 price target after its recent cross-listing from the London Stock Exchange to NASDAQ. The stock closed at $13.52 on May 19...

BTIG launched coverage of Axsome Therapeutics (NASDAQ:AXSM) with a “buy” rating and $14 price target. The stock closed at $3.80 on May 18. Axsome is developing novel therapies for pain and central nervous system...

Leerink initiated coverage of Arena Pharmaceuticals (NASDAQ:ARNA) with an “outperform” rating and $5 price target. The stock closed at $1.15 on May 18. “Following a strategic reorganization led by a new management team...

Leerink upgraded Achillion Pharmaceuticals (NASDAQ:ACHN) to “outperform” from “market perform” and raised its price target to $6 from $4. The stock closed at $3.78 on May 17. Achillion has a portfolio of direct...

Maxim Group slashed its price target for Stellar Biotechnologies (NASDAQ:SBOT) to $2 from $4, but maintained its “buy” rating, after the company reported fiscal second quarter results. The stock closed at $1.32 on May 9...